Mepolizumab (IL5) Antibody, Monoclonal | 10-123

Mepolizumab (IL5) Antibody, Monoclonal | 10-123 | Gentaur UK, US & Europe Distribution

Host: N/A

Reactivity: N/A

Homology: N/A

Immunogen: Humanized / IL5 [Homo sapiens]

Research Area: Drug Analogues

Tested Application: N/A

Application: N/A

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: >95%

Clonality: Monoclonal

Clone: N/A

Isotype: IgG1-kappa

Conjugate: Unconjugated

Physical State: N/A

Buffer: PBS buffer pH7.5

Concentration: N/A

Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.

Alternate Name: SB-240563, IL5, IL5

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Mepolizumab is a humanized IL-5 antagonist monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary cells.It has a molecular weight of approximately 149 kDa.It was approved by the FDA in November, 2015 for the treatment of asthma under the brand name Nucala (marketed by GlaxoSmithKline) .Mepolizumab has been investigated in the treatment of severe nasal polyposis, among numerous other conditions.Mepolizumab is an interleukin-5 antagonist (IgG1 kappa) .IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils.Mepolizumab binds to IL-5 with a dissociation constant of 100 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface.Inflammation is an important component in the pathogenesis of asthma. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in inflammation.Mepolizumab, by inhibiting IL-5 signaling, reduces the production and survival of eosinophils;however, the mechanism of mepolizumab action in asthma has not been definitively established.